These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 31883703)

  • 1. A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers.
    Portron A; Jordan P; Draper K; Muenzer C; Dickerson D; van Iersel T; Hofmann C
    Clin Ther; 2020 Jan; 42(1):108-120.e1. PubMed ID: 31883703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tezepelumab Pharmacokinetics, Safety, and Tolerability After Administration via Vial-and-syringe, Accessorized Prefilled Syringe, or Autoinjector: A Randomized Trial in Healthy Volunteers.
    Zheng Y; Abuqayyas L; Megally A; Fuhr R; Sałapa K; Downie J; Colice G
    Clin Ther; 2021 Jan; 43(1):142-155.e5. PubMed ID: 33380362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact.
    Boess FG; Scelsi MA; Grimmer T; Perry RJ; Tonietto M; Klein G; Hofmann C; Salami M; Wojtowicz J; Lansdall CJ; Lane C; Kerchner GA; Smith J; Doody RS
    J Prev Alzheimers Dis; 2024; 11(3):537-548. PubMed ID: 38706270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability of High-Volume Subcutaneous Injections of a Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy Subjects.
    Dias C; Abosaleem B; Crispino C; Gao B; Shaywitz A
    AAPS PharmSciTech; 2015 Oct; 16(5):1101-7. PubMed ID: 25693652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK9, after single subcutaneous injection at three sites [NCT 02043301].
    Wang EQ; Plotka A; Salageanu J; Sattler C; Yunis C
    Cardiovasc Ther; 2017 Oct; 35(5):. PubMed ID: 28636184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD).
    Neve A; Das B; Wojtowicz J; Huang Z; Bullain S; Watkin M; Lott D; Bittner T; Delmar P; Klein G; Hofmann C; Kerchner GA; Smith J; Baudler M; Fontoura P; Doody RS
    J Alzheimers Dis; 2024; 101(1):353-367. PubMed ID: 39177596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers.
    Dychter SS; Harrigan R; Bahn JD; Printz MA; Sugarman BJ; DeNoia E; Haughey DB; Fellows D; Maneval DC
    Clin Ther; 2014 Feb; 36(2):211-24. PubMed ID: 24486335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of a humanized rabbit monoclonal antibody (SSS07) in healthy adults: Randomized double-blind placebo-controlled single ascending dose trial.
    Liu C; Dong W; Xia L; Lv J; Jiang D; Wang Q; Wang M; Wu M; Miao J; Tao T; Wang D; Zheng L; Su S; Liu L; Fang Y
    Int Immunopharmacol; 2021 Feb; 91():107263. PubMed ID: 33383447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and tolerability of sumatriptan after single-dose administration of a fixed-dose combination tablet of sumatriptan/naproxen sodium 85/500 mg followed two hours later by subcutaneous sumatriptan 4- or 6-mg injection: a randomized, open-label, three-period crossover study in healthy volunteers.
    Berges A; Walls C; Lener SE; McDonald SA
    Clin Ther; 2010 Jun; 32(6):1165-77. PubMed ID: 20637969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.
    Ostrowitzki S; Lasser RA; Dorflinger E; Scheltens P; Barkhof F; Nikolcheva T; Ashford E; Retout S; Hofmann C; Delmar P; Klein G; Andjelkovic M; Dubois B; Boada M; Blennow K; Santarelli L; Fontoura P;
    Alzheimers Res Ther; 2017 Dec; 9(1):95. PubMed ID: 29221491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study.
    Nemoto O; Furue M; Nakagawa H; Shiramoto M; Hanada R; Matsuki S; Imayama S; Kato M; Hasebe I; Taira K; Yamamoto M; Mihara R; Kabashima K; Ruzicka T; Hanifin J; Kumagai Y
    Br J Dermatol; 2016 Feb; 174(2):296-304. PubMed ID: 26409172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial.
    Heise T; Nosek L; Dellweg S; Zijlstra E; Præstmark KA; Kildegaard J; Nielsen G; Sparre T
    Diabetes Obes Metab; 2014 Oct; 16(10):971-6. PubMed ID: 24720741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the safety, tolerability, and PK/PD properties of two new formulations of subcutaneously administered IFN-beta1a: a double-blind, placebo-controlled comparison with the currently available formulation.
    Brearley C; Jaber A; Bertolino M; Priestley A; Seiberling M
    Int J Clin Pharmacol Ther; 2007 Jun; 45(6):307-18. PubMed ID: 17595888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Stapokibart in Healthy Volunteers and Adult Subjects with Atopic Dermatitis.
    Zhang L; Zhang W; Xu Y; Dong L; Sun Y; Jia Y; Li Z; Chen B; Hou J; Zhang J
    Adv Ther; 2024 Jul; 41(7):2953-2965. PubMed ID: 38833140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the tolerability of recombinant human hyaluronidase + normal saline and recombinant human hyaluronidase + lactated ringer's solution administered subcutaneously: A phase IV, double-blind, randomized pilot study in healthy volunteers.
    Dychter SS; Ebel D; Mead TR; Yocum RC
    Curr Ther Res Clin Exp; 2009 Dec; 70(6):421-38. PubMed ID: 24692835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.
    Albach FN; Wagner F; Hüser A; Igel J; Joseph D; Hilbert J; Schoelch C; Padula SJ; Steffgen J
    Eur J Clin Pharmacol; 2018 Feb; 74(2):161-169. PubMed ID: 29127458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects.
    Struemper H; Murtaugh T; Gilbert J; Barton ME; Fire J; Groark J; Fox NL; Roth D; Gordon D
    Clin Pharmacol Drug Dev; 2016 May; 5(3):208-15. PubMed ID: 27163500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tralokinumab pharmacokinetics and tolerability when administered by different subcutaneous injection methods and rates
.
    Jain M; Doughty D; Clawson C; Li X; White N; Agoram B; van der Merwe R
    Int J Clin Pharmacol Ther; 2017 Jul; 55(7):606-620. PubMed ID: 28590244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
    Bateman RJ; Smith J; Donohue MC; Delmar P; Abbas R; Salloway S; Wojtowicz J; Blennow K; Bittner T; Black SE; Klein G; Boada M; Grimmer T; Tamaoka A; Perry RJ; Turner RS; Watson D; Woodward M; Thanasopoulou A; Lane C; Baudler M; Fox NC; Cummings JL; Fontoura P; Doody RS;
    N Engl J Med; 2023 Nov; 389(20):1862-1876. PubMed ID: 37966285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and Safety of Spesolimab in Healthy Chinese Subjects: An Open-Label, Phase I Study.
    Cao G; Yang H; Wang J; Ishida M; Thoma C; Haeufel T; Bossert S; Zhang J
    Adv Ther; 2024 Sep; 41(9):3557-3568. PubMed ID: 39039387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.